Early Amino Acid Intake in ELBW Infants: School-Aged Outcomes From a Randomized Controlled Trial

David A Nyakotey1, Gavin T L Brown2, Barbara E Cormack1,3

  • 1Liggins Institute, University of Auckland, Auckland, New Zealand.

Pediatrics
|June 4, 2026
PubMed

Insights

Providing extra parenteral amino acids to extremely low birthweight (ELBW) infants did not improve neurocognitive outcomes. This intervention may negatively impact muscle strength and psychosocial functioning in ELBW children.

Area of Science:

  • Neonatal Medicine
  • Pediatric Nutrition
  • Developmental Neuroscience

Background:

  • Extremely low birthweight (ELBW) infants face significant risks for neurodevelopmental and physical challenges.
  • Optimizing early nutrition, including parenteral amino acids, is crucial for improving outcomes in ELBW infants.
  • The long-term effects of supplemental parenteral amino acids on neurocognitive function and physical development require further investigation.

Purpose of the Study:

  • To determine if additional parenteral amino acids in ELBW infants enhance neurocognitive function, lean mass, and muscle strength.
  • To assess the safety of this intervention regarding blood pressure and general health at school age.
  • To evaluate the impact on survival free of neurocognitive impairment.

Main Methods:

  • A multicenter, double-blinded, randomized trial compared additional parenteral amino acids (1 g/d for 5 days) versus placebo in ELBW infants.
  • Follow-up occurred at 6 to 7 years corrected age, assessing neurocognitive function using the NIH Toolbox.
  • Primary outcome was survival without neurocognitive impairment; secondary outcomes included measures of strength, body composition, and psychosocial health.

Main Results:

  • No significant difference was observed in survival free of neurocognitive impairment between the amino acid and placebo groups (21% vs 23%).
  • Children receiving additional amino acids exhibited lower muscle strength (relative handgrip strength z-score: -0.73 vs -0.33).
  • A potential increased risk of low psychosocial functioning was noted in the amino acid group (26% vs 18%).

Conclusions:

  • Supplemental parenteral amino acids for 5 days in ELBW infants show minimal to no benefit for neurocognitive outcomes at school age.
  • The intervention may be associated with adverse effects on muscle strength and psychosocial functioning.
  • Current evidence suggests limited long-term advantages and potential risks, warranting cautious consideration of this nutritional strategy.
Abstract

Related Concept Videos

Bioavailability Study Design: Absolute Versus Relative Bioavailability01:27

Bioavailability Study Design: Absolute Versus Relative Bioavailability

Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Parentral Nutrition: Centeral and Peripheral Parental Nutrition01:27

Parentral Nutrition: Centeral and Peripheral Parental Nutrition

Parenteral Nutrition (PN) delivers essential nutrients directly into the bloodstream, bypassing the digestive system. It is commonly used for individuals with severe digestive disorders or conditions that prevent normal nutrient absorption.
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...